Alec Stranahan
Stock Analyst at B of A Securities
(1.17)
# 2,680
Out of 4,502 analysts
21
Total ratings
58.33%
Success rate
-23.22%
Average return
Main Sectors:
Top Industries:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Buy | $48 → $55 | $46.50 | +18.28% | 3 | Jul 16, 2024 | |
| NVAX Novavax | Maintains: Neutral | $12 → $18 | $15.40 | +16.88% | 3 | Jun 14, 2024 | |
| ERAS Erasca | Downgrades: Neutral | $11 → $6 | $3.11 | +92.93% | 1 | Jan 5, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $118 → $140 | $206.64 | -32.25% | 3 | May 25, 2023 | |
| XNCR Xencor | Initiates: Buy | $42 | $20.41 | +105.78% | 1 | May 19, 2023 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $6 → $12 | $12.37 | -2.99% | 4 | May 15, 2023 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Underperform | $34 → $9 | $15.39 | -41.52% | 2 | Apr 25, 2023 | |
| TGTX TG Therapeutics | Maintains: Underperform | $5 → $6 | $19.58 | -69.36% | 2 | Dec 29, 2022 | |
| HOOK HOOKIPA Pharma | Downgrades: Underperform | $60 → $5 | $6.02 | -16.94% | 1 | Dec 2, 2022 | |
| SWTX SpringWorks Therapeutics | Initiates: Buy | $45 | $36.66 | +22.75% | 1 | Dec 1, 2022 |
Revolution Medicines
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $46.50
Upside: +18.28%
Novavax
Jun 14, 2024
Maintains: Neutral
Price Target: $12 → $18
Current: $15.40
Upside: +16.88%
Erasca
Jan 5, 2024
Downgrades: Neutral
Price Target: $11 → $6
Current: $3.11
Upside: +92.93%
Krystal Biotech
May 25, 2023
Maintains: Buy
Price Target: $118 → $140
Current: $206.64
Upside: -32.25%
Xencor
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $20.41
Upside: +105.78%
Y-mAbs Therapeutics
May 15, 2023
Maintains: Neutral
Price Target: $6 → $12
Current: $12.37
Upside: -2.99%
Day One Biopharmaceuticals
Apr 25, 2023
Downgrades: Underperform
Price Target: $34 → $9
Current: $15.39
Upside: -41.52%
TG Therapeutics
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $19.58
Upside: -69.36%
HOOKIPA Pharma
Dec 2, 2022
Downgrades: Underperform
Price Target: $60 → $5
Current: $6.02
Upside: -16.94%
SpringWorks Therapeutics
Dec 1, 2022
Initiates: Buy
Price Target: $45
Current: $36.66
Upside: +22.75%